Work

81P Predictive value of inflammatory ratios on the outcome of advanced melanoma patients treated with anti-PD1 monotherapy: A multicentric analysis

Year: 2024

Type: article

Abstract: cancers, first radiological response, number of prior lines of therapy, progression free survival (PFS), overall survival (OS) were assessed, as well as tumor markers at baseline, at 1 st evaluation and in-between when available.Results: Out of the 147 pts treated with TCE, 67 had an informative tumor marker (CEA, CA125, PSA), including 51.5% had prostate cancer, 20.3% ovarian carcinoma, 22.1% colorectal cancer, 2.9% breast cancer and 2.9% pancreatic cancer.Median (md) prior lines was 4; md PFS 2.2 months (m), md OS 7.3 m.Overall response rate was 3% (2/67 pts).Pts had a median age of 62 years old at baseline.68 had tumor marker dosed at baseline, 63 at an intermediate timepoint and 67 at the first radiologic reevaluation.Out of 27 pts who had a decrease in tumor markers, 7.4% (2) presented a partial response, 59.3% (16) remained stable and 33.3% (9) had progressive disease.Among the 38 pts with increased tumor markers, 71% (27) showed progression, 29% (11) remained stable and no patient presented a partial response.The 2 patients with stable tumor markers showed radiological progression. Conclusions:In our retrospective analysis, preliminary results showed that evolution of serum tumor markers didn't seemed to be a good surrogate for the radiological response in patients receiving T-cell engager therapy.The cohort will be extended prospectively to other centers to implement additional patients and data and further analyses including intermediate time points and spaghetti plots figures will be presented at the congress.

Source: Immuno-Oncology Technology

DOI: 10.1016/j.iotech.2024.100824